Cost Cutting Is Nice, But Don't Forget About Sales

Don't let it get away!

Keep track of the stocks that matter to you.

Help yourself with the Fool's FREE and easy new watchlist service today.

Everyone is focused on Dendreon's (NASDAQOTH: DNDNQ  ) cost-cutting measures to get the biotech to profitability. And for good reason -- in the fourth quarter of 2011, a whopping 74% of net product sales were used to manufacture its prostate cancer treatment, Provenge. It's hard to turn a profit when costs are that high.

The company is slowly working toward its goal of getting the cost down to 50% of sales; in the fourth quarter, manufacturing costs were under 64% of net sales. Selling, general, and administrative costs were also down year over year.

That's all good news for sure, but I don't think investors should forget about sales growth. You can only cut costs to a certain point; sales growth can theoretically go on forever.

Excluding adjustments for a chargeback that boosted revenue slightly, fourth-quarter Provenge sales were up 5% over the previous quarter. That's not too shabby. At that rate, Dendreon could be above its sales target of $100 million per quarter to be cash flow positive in the fourth quarter of this year.

Unfortunately, it doesn't look like we'll see that same growth in the first quarter. According to management, it's not prostate cancer treating season.

That's right -- Dendreon blamed "seasonality" on an expected slowdown in sales.

We've seen this with other drugmakers. Biogen Idec (NASDAQ: BIIB  ) and Elan (UNKNOWN: ELN.DL2  ) blamed slower growth of their multiple sclerosis drug Tysabri on summer vacations. Edwards Lifesciences (NYSE: EW  ) blamed doctors going on vacation for missing revenue guidance last year.

In Dendreon's case, the company thinks sales are light in the beginning of the year because doctors want to verify insurance, which can change at the end of the year. Doctors are on the hook to pay for the rather expensive drug and are reimbursed by the insurance companies, so it's reasonable for them to make sure they can get paid back. This isn't the first year we've seen this issue in early January, so I'm willing to give Dendreon a pass.

The problem for investors is that it's going to be hard to separate seasonality from the recent expanded FDA approval of Johnson & Johnson's (NYSE: JNJ  ) Zytiga into pre-chemotherapy patients, the same prostate cancer patients that Provenge is approved to treat. We'll likely have to wait until second quarter sales numbers are released before we know if the first-quarter headwinds were temporary or a permanent issue from competition with Zytiga.

Resurgence, or dead cat bounce?
Shares of Dendreon  are well off the 52-week low they set last year. Has the company really solved its underlying problems, or are investors setting themselves up for more disappointment? Our new premium research report on Dendreon answers these questions, and many more, while also outlining just how Dendreon intends to regain its former glory. Claim your copy, and a year of free analyst updates, by clicking here now.

Read/Post Comments (1) | Recommend This Article (2)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On February 26, 2013, at 10:02 PM, lebronz wrote:

    Do any of you Fewls think before you write an article on dndn?

    30,000 men are newly diagnosed with mCRPC during a year (7500/quarter) and 60,000 are living with mCRPC (these men typically live 2 years after initial diagnosis).

    Given dndn is only treating on average in 2012, about 860 men per quarter ($80M), all they have to do is treat 1076 men in a quarter to reach $100M ($93k x 1076 = $100M).

    Do you really think it will be that hard for dndn to treat an additional 216 men in a quarter given they keep increasing accounts/infusion sites?



    ps: Well, on second thought, because this new CEO caters to his top 10 largest shareholders and wallstreet analysts and because major institutions want in dndn before they bust through treating 1076 patients in a quarter..., as they have been accumulating millions (eg: Vanguard, Deerfield, and Blackrock) while shorting nearly 2 million shares per month over the last 17 months...from 14 million to 50 million today, you might be right about your Q4 prediction.

Add your comment.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2279791, ~/Articles/ArticleHandler.aspx, 9/27/2016 3:32:06 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
DOW 18,215.63 120.80 0.67%
S&P 500 2,158.22 12.12 0.56%
NASD 5,300.51 43.02 0.82%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/27/2016 3:16 PM
BIIB $313.83 Up +4.01 +1.29%
Biogen CAPS Rating: *****
DNDNQ $0.00 Down +0.00 +0.00%
Dendreon Corp CAPS Rating: *
ELN.DL2 $0.00 Down +0.00 +0.00%
Elan CAPS Rating: ***
EW $121.28 Up +2.34 +1.97%
Edwards Lifescienc… CAPS Rating: ****
JNJ $118.97 Up +1.19 +1.01%
Johnson and Johnso… CAPS Rating: *****